tirzepatide made of Tirzepatide, a New Era Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Tirzepatide is a groundbreaking, once-weekly

Description

Results showed that a greater proportion of subjects in the placebo group experienced MACE over the follow-up period (701 of 8,801 patients, or 8.0%) than in the semaglutide group (569 of 8,803 patients, or 6.5%)

Moreover, GLP-1RAs can alleviate vascular remodeling expressed as neointimal hyperplasia after induced vascular injury

People who binge eat and people with a higher BMI are more likely to show certain impulsive behaviours.[3] And people taking GLP-1 drugs report less impulsive and compulsive shopping.[4] In this interview, Dr Guen Bradbury talks with Dr Eve McMahon about how medicine has been surprised by the increase in use of GLP-1 drugs, and what this means for the future